Costs of care for Crohns disease following the introduction of infliximab: A single-centre UK experience

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 11-12, 2010, Pages 1357-1363

  Sprakes, M B ^a   Ford, A C ^a   Suares, N C ^a   Warren, L ^a   Greer, D ^a   Donnellan, C F ^a   Jennings, J S R ^a   Everett, S M ^a   Hamlin, P J ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CROHN DISEASE; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM; ADOLESCENT; COST BENEFIT ANALYSIS; ECONOMICS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; COST-BENEFIT ANALYSIS; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78449289970     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04482.x     Document Type: Article

References (19)

1. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohns disease: a payor perspective. Am J Gastroenterol 2000; 95: 1955 - 60.
2. Drossman DA,. Measuring quality of life in inflammatory bowel disease. Pharmacoeconomics 1994; 6: 578 - 80.
3. Donnellan CF, Ford AC, Sprakes MB, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009; 21: 71 - 5.
4. Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. Crohns Disease cA2 Study Group. N Engl J Med 1997; 337: 1029 - 35.
5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohns disease. N Engl J Med 1999; 340: 1398 - 405.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. for the ACCENT I Study Group. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541 - 9.
7. Harvey RF, Bradshaw JM,. A simple index of Crohns disease activity. Lancet 1980; 1: 514.
8. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A): 5 - 36.
9. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471 - 8.
10. Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohns disease-modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008; 28: 76 - 87.
11. Bodger K, Kikuchi T, Hughes D,. Cost-effectiveness of biological therapy for Crohns disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009; 30: 265 - 74.
12. Crohns disease - infliximab (review) and adalimumab (review of TA40). May 2010. Available at:. Accessed September 30, 2010.
13. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohns disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17: 1047 - 52.
14. Saro C, Da La Coba C, Casado MA, et al. Resource use in patients with Crohns disease treated with infliximab. Aliment Pharmacol Ther 2007; 26: 1313 - 23.
15. Rubenstein JH, Chong RY, Cohen RD,. Infliximab decreases resource use among patients with Crohns disease. J Clin Gastroenterol 2002; 35: 151 - 6.
16. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohns disease. Gastroenterology 2006; 130: 650 - 6.
17. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohns disease trial. N Engl J Med 2010; 362: 1383 - 95.
18. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohns disease. Inflamm Bowel Dis 2009; 15: 1295 - 301.
19. Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab discontinuation in Crohns disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009; 136 (Suppl. 1): A-146.